Open
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Grant from European Commission (Horizon Europe)
- Funder
- European Commission (Horizon Europe)
- Award amount
- $7,000,000 – $9,000,000
- Deadline
- September 21, 2027
- Status
- Open
- Official source
- ec.europa.eu
Open in GrantAuthority. The full listing, application link, requirements, attachments, program contacts and your organization's fit score are available with a free account.